Should I buy or sell Hoth Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOTH shares. View HOTH analyst ratings or view top-rated stocks .

What is Hoth Therapeutics' stock price target for 2024?

2 equities research analysts have issued 1 year price targets for Hoth Therapeutics' shares. Their HOTH share price targets range from $5.00 to $14.00. On average, they predict the company's share price to reach $9.50 in the next year. This suggests a possible upside of 733.3% from the stock's current price. View analysts price targets for HOTH or view top-rated stocks among Wall Street analysts .

How have HOTH shares performed in 2023?

Hoth Therapeutics' stock was trading at $7.80 at the beginning of the year. Since then, HOTH shares have decreased by 85.4% and is now trading at $1.14. View the best growth stocks for 2023 here .

Are investors shorting Hoth Therapeutics?

Hoth Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 29,700 shares, an increase of 19.8% from the October 31st total of 24,800 shares. Based on an average daily trading volume, of 213,600 shares, the short-interest ratio is currently 0.1 days. Currently, 0.7% of the company's shares are sold short. View Hoth Therapeutics' Short Interest .

When is Hoth Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our HOTH earnings forecast .

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($3.50) EPS for the quarter, missing analysts' consensus estimates of ($3.38) by $0.13.

When did Hoth Therapeutics' stock split?

Shares of Hoth Therapeutics reverse split before market open on Wednesday, October 26th 2022. The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR) , Ocugen (OCGN) , Fulcrum Therapeutics (FULC) , Heat Biologics (HTBX) , Tonix Pharmaceuticals (TNXP) , AIM ImmunoTech (AIM) , Aytu BioPharma (AYTU) , Gilead Sciences (GILD) , iBio (IBIO) and Nabriva Therapeutics (NBRV) .

When did Hoth Therapeutics IPO?

(HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Hoth Therapeutics Stock Price, News & Analysis (NASDAQ:HOTH)

$1.14

+0.04 (+3.64%)

(As of 11/28/2023 ET)

Compare

Today's Range: $1.11
▼
$1.15
50-Day Range: $1.03
▼
$1.75
52-Week Range: $0.99
▼
$12.50

Volume: 37,261 shs
Average Volume: 808,532 shs
Market Capitalization: $4.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.50

Hoth Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 733.3% Upside
$9.50 Price Target
Short Interest: Healthy
0.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.87
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Hoth Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.50, Hoth Therapeutics has a forecasted upside of 733.3% from its current price of $1.14.
Amount of Analyst Coverage
Hoth Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.69% of the float of Hoth Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Hoth Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Hoth Therapeutics has recently increased by 19.76%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Hoth Therapeutics does not currently pay a dividend.
Dividend Growth
Hoth Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HOTH.

3.8

News and Social Media Coverage

News Sentiment
Hoth Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Hoth Therapeutics this week, compared to 1 article on an average week.
Search Interest
1 people have searched for HOTH on MarketBeat in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hoth Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.29% of the stock of Hoth Therapeutics is held by insiders.
Percentage Held by Institutions
Only 2.17% of the stock of Hoth Therapeutics is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Hoth Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hoth Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Hoth Therapeutics has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Hoth Therapeutics Stock (NASDAQ:HOTH)

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

HOTH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HOTH Stock News Headlines

November 14, 2023 | markets.businessinsider.com

Hoth Completes Pre-IND Meeting With FDA On Development Of HT-KIT Therapeutic

November 14, 2023 | finance.yahoo.com

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 10, 2023 | finance.yahoo.com

Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023

October 5, 2023 | finance.yahoo.com

Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery

October 2, 2023 | markets.businessinsider.com

Hoth Therapeutics: FDA Grants Pre-IND Meeting For HT-KIT; Stock Surges

October 2, 2023 | finance.yahoo.com

FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients

September 15, 2023 | nasdaq.com

EF Hutton Maintains Hoth Therapeutics (HOTH) Buy Recommendation

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

September 15, 2023 | finance.yahoo.com

Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

September 13, 2023 | markets.businessinsider.com

Hoth Therapeutics Reports Positive Preclinical Results Of HT-KIT Therapeutic; Stock Surges

September 13, 2023 | marketwatch.com

Hoth Therapeutics Shares Rise 7% After Positive Study Data for HT-KIT

September 13, 2023 | msn.com

Hoth stock tumbles on $2.9M direct offering, private placement

September 13, 2023 | marketwatch.com

Hoth Therapeutics Shares Drop 23% After Direct Offering Prices

September 13, 2023 | msn.com

Hoth Therapeutics' Investigational Cancer Drug Shows Encouraging Preclinical Activity In Stomach Cancers

September 13, 2023 | finance.yahoo.com

Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

September 13, 2023 | finance.yahoo.com

Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

September 11, 2023 | markets.businessinsider.com

Hoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDA

September 11, 2023 | finance.yahoo.com

Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients

September 6, 2023 | markets.businessinsider.com

Hoth Therapeutics Reports Positive Results From Phase 1b Trial Of BioLexa

September 6, 2023 | finance.yahoo.com

Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa

August 9, 2023 | msn.com

Hoth Therapeutics Alzheimer's Treatment Shows Improvement In Cognitive Function, Anxiety

August 9, 2023 | finance.yahoo.com

Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease

July 19, 2023 | markets.businessinsider.com

Hoth Receives Protocol Approval For HT-001 Cancer Therapeutic; Stock Up

June 20, 2023 | markets.businessinsider.com

Benchmark Co. Remains a Buy on Hoth Therapeutics (HOTH)

June 20, 2023 | markets.businessinsider.com

Analyst Expectations for Hoth Therapeutics's Future

June 20, 2023 | benzinga.com

Benchmark Reiterates Speculative Buy on Hoth Therapeutics, Maintains $5 Price Target

See More Headlines

Receive HOTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/29/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HOTH
CUSIP: N/A
CIK: 1711786
Web: www.hoththerapeutics.com
Phone: (646) 756-2997
Fax: N/A
Employees: 2
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.50
High Stock Price Target: $14.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +733.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,370,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -102.79%
Return on Assets: -87.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.63
Quick Ratio: 7.63

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.56 per share
Price / Book: 0.32

Miscellaneous

Outstanding Shares: 4,346,000
Free Float: 4,203,000
Market Cap: $4.95 million
Optionable: Not Optionable
Beta: 0.58

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Robb Knie (Age 54)
President, CEO & Chairman
Comp: $844.01k
Mr. David S. Briones (Age 47)
Chief Financial Officer
Ms. Hayley Springer
Executive Vice President of Operations

Key Competitors

View All Competitors

HOTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Hoth Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOTH shares.
View HOTH analyst ratings or view top-rated stocks.
What is Hoth Therapeutics' stock price target for 2024?: 2 equities research analysts have issued 1 year price targets for Hoth Therapeutics' shares. Their HOTH share price targets range from $5.00 to $14.00. On average, they predict the company's share price to reach $9.50 in the next year. This suggests a possible upside of 733.3% from the stock's current price.
View analysts price targets for HOTH or view top-rated stocks among Wall Street analysts.
How have HOTH shares performed in 2023?: Hoth Therapeutics' stock was trading at $7.80 at the beginning of the year. Since then, HOTH shares have decreased by 85.4% and is now trading at $1.14.
View the best growth stocks for 2023 here.
Are investors shorting Hoth Therapeutics?: Hoth Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 29,700 shares, an increase of 19.8% from the October 31st total of 24,800 shares. Based on an average daily trading volume, of 213,600 shares, the short-interest ratio is currently 0.1 days. Currently, 0.7% of the company's shares are sold short.
View Hoth Therapeutics' Short Interest.
When is Hoth Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our HOTH earnings forecast.
How were Hoth Therapeutics' earnings last quarter?: Hoth Therapeutics, Inc. (NASDAQ:HOTH) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($3.50) EPS for the quarter, missing analysts' consensus estimates of ($3.38) by $0.13.

When did Hoth Therapeutics' stock split?: Shares of Hoth Therapeutics reverse split before market open on Wednesday, October 26th 2022. The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of Hoth Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM), Aytu BioPharma (AYTU), Gilead Sciences (GILD), iBio (IBIO) and Nabriva Therapeutics (NBRV).
When did Hoth Therapeutics IPO?: (HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.
How do I buy shares of Hoth Therapeutics?: Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HOTH) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial